Imeik Technology Development Co.,Ltd., once hailed as the "A-share gem of aesthetic medicine," is facing its most severe credibility crisis since going public. The 2025 annual report reveals comprehensive declines in core profitability metrics for this industry leader, whose market value once soared to hundreds of billions on the strength of its "Haiti" injectable product. The company confronts multiple challenges including failed overseas expansion through arbitration setbacks, overdependence on single products, growth stagnation, and compliance risks. Market participants are reevaluating the company's previous narrative of "high margins and high growth."
First, Three Consecutive Quarterly Declines Despite High Dividend Payouts In 2025, Imeik Technology reported operating revenue of 2.453 billion yuan, down 18.94% year-over-year. Net profit attributable to shareholders reached 1.291 billion yuan, declining 34.05%, while adjusted net profit plummeted 41.30% to 1.099 billion yuan. This marks the first simultaneous decline across all three core profitability metrics since its IPO, indicating accelerated deterioration of fundamental earning capacity. Despite distributing 603 million yuan in cash dividends with a payout ratio of approximately 46.70%, the market responded negatively. Since late January 2026, the company's stock price has trended downward, accumulating nearly 30% losses over the past year. Market capitalization has shrunk to around 36 billion yuan, nearly 80% below its peak of nearly 180 billion yuan in 2021, now even lower than its first-day listing valuation. Financial institutions have downgraded earnings forecasts and target prices, reflecting cooled growth expectations for 2026.
Second, Flagship Product Haiti Shows First Decline Amid Overconcentration Imeik Technology's growth story has long relied on its superstar product Haiti. In 2025, revenue from solution-based injectables (primarily Haiti) experienced its first double-digit decline, while gel-based injectables also showed weakness. Together these products still constitute over 95% of total revenue, demonstrating extreme product concentration and vulnerability to market shifts. As competitors including Bloomage Biotech and Haohai Healthcare accelerate product innovation and channel expansion, supplemented by smaller brands capturing market share through aggressive pricing, Imeik Technology's core products continue losing market presence. Price advantages have diminished significantly with substantial customer attrition. Intensified industry competition combined with macroeconomic pressures suppressing consumer demand is pushing the company's single-product growth model to its breaking point.
Third, Overseas Expansion Falters with 1.6 Billion Yuan Arbitration Overhang Seeking alternative growth drivers, Imeik Technology aggressively pursued international expansion, acquiring 85% of South Korea's REGEN Biotech for $190 million in 2025—a record cross-border transaction in China's aesthetic medicine sector. However, overseas operations contributed merely 46.84 million yuan in revenue, representing less than 2% of total revenue. More critically, the acquisition triggered ongoing arbitration disputes. After unilaterally terminating its exclusive distribution agreement with Dato Medical, the latter filed claims totaling 1.6 billion yuan—exceeding Imeik Technology's entire 2025 net profit. Although arbitrators revoked interim measures in late January 2026, the case remained unresolved as of April 2026, creating significant contingent liability risks.
Fourth, Low R&D Conversion Meets Tightening Regulatory Environment The company invested 360 million yuan in research and development during 2025, an 18.45% increase year-over-year, but demonstrated low conversion efficiency with most projects focusing on incremental improvements rather than breakthrough innovations. New products including "Gukela" and minoxidil topical solution received tepid market response, while its type-A botulinum toxin operates under distribution arrangements posing substantial market penetration challenges. Concurrently, regulatory oversight in the aesthetic medicine industry continues tightening. New rules effective 2026 impose strict controls on social media promotion of medical aesthetic products and mandate traceability scanning for medical devices, potentially dampening downstream clinic operations and consequently suppressing upstream product demand. Recent penalties against distributors for improper storage of Haiti products further exposed weaknesses in the company's terminal compliance management.
Conclusion: From Shortage Concerns to Growth Challenges Imeik Technology's decline from "product scarcity" to "growth scarcity" reflects systemic rather than incidental factors. Overreliance on single products, weak organic growth, overseas expansion risks, and compliance vulnerabilities—compounded by industry-wide regulatory tightening and competitive deterioration—create unprecedented systemic challenges. The unresolved 1.6 billion yuan arbitration case may ultimately crush remaining market confidence. Unless the company can rapidly rebuild its product portfolio and resolve major legal risks, its former glory as the "aesthetic medicine gem" may become permanently historical.
Comments